Table 5

Triple therapy (OAC+DAPT)

IndicationTherapyDuration of triple therapyGuideline
Indication for therapeutic anticoagulation and PCI <1 monthOAC+ASA+ clopidogrel1 month after PCI*
Followed by OAC+SAPT for 12 months after PCI, followed by OAC therapy lifelong†
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease.9
Atrial fibrillation, NSTEMI and PCI <1 weekOAC+ASA+ clopidogrel1 week after PCI‡
Followed by OAC+SAPT for 12 months after PCI, followed by OAC therapy lifelong†
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.18
  • *Longer duration till 6 months can be considered in patients with a high ischaemic risk or patients with a mechanical valve.

  • †Unless the therapeutic anticoagulation therapy is stopped, in which case ASA or clopidogrel should be started.

  • ‡Longer duration till 1 month can be considered in patients with a high ischaemic risk.

  • ACS, acute coronary syndrome; ASA, acetylsalicylic acid; ESC, European Society of Cardiology; NSTEMI, non-ST-elevation myocardial infarction; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy.